Patients with major depressive disorder (MDD) report a broad range of treatment goals that go beyond symptom control (1)

Patient-reported treatment goals in MDD include generalised goals, as well as specific physical, social and cognitive goals.1

A survey study by McNaughton EC et al. explored the shared decision-making and goal attainment approach to establishing and tracking progress toward treatment goals that are meaningful to individual patients in real-world clinical practice.1 Of the 200 participants who completed the survey, 42% reported currently having goals for MDD treatment, ranging from the areas of physical health to social aspects of life.1

A majority of respondents (61%) believed the goal attainment approach would be helpful to set and evaluate treatment goals in their recovery, therefore the results of this study can be used to inform best practices in patient-clinician communication when developing an MDD treatment plan and goals.1

Explore the range of patient-reported treatment goals in MDD below.
 

Patient-reported treatment goals in MDD1

Adapted from: McNaughton EC et al. 2019

References

  1. McNaughton EC et al. Patient Prefer Adherence 2019; 13: 959-967.

Internal ID: AU-BRIN-0480. September 2022.

  • Brintellix
    Body

    Brintellix® é indicado para o tratamento de episódios depressivos major em adultos

  • footer text
    Body

    A informação contida nesta página destina-se exclusivamente a profissionais de saúde.

    Recebeu este e-mail porque consentiu anteriormente em receber e-mails da Lundbeck.
    Brintellix® é uma marca registrada da H/Lundbeck A/S.

    Representante local do Titular da Autorização de Introdução no Mercado:

    Lundbeck Portugal

    Quinta da Fonte
    Rua Quinta da Fonte, Nº 13
    Edifício Q34 Forum, Piso 1, Fração F
    2770-192 Paço de Arcos. Portugal
    NIF 503573922

    Tlf.: +351 21 004 5900 | Fax: +351 21 004 5999

    www.lundbeck.pt